Keck School Faculty

Paula Cannon, PhD
Paula Cannon, PhD
Distinguished Professor of Molecular Microbiology & Immunology
Molecular Microbiology and Immunology
HMR 413A 2011 Zonal Avenue Health Sciences Campus Los Angeles
Cannon Lab Website

Paula Cannon, PhD, is an Associate Professor of Microbiology at the Keck School of Medicine of USC, where she leads a research team that studies viruses, stem cells and gene therapy. She obtained her PhD from the University of Liverpool in the United Kingdom, and received postdoctoral training as an HIV scientist at both Oxford and Harvard universities. Although HIV remains the main focus of her work, she also studies highly pathogenic hemorrhagic fever viruses, including Ebola and Lassa fever viruses. Cannon has a long-standing interest in the development of gene therapy as a clinical approach to treating HIV infection, and her recent work in this area is aimed at disrupting the viral co-receptor, CCR5, using zinc finger nucleases (ZFNs). This approach is being evaluated in human hematopoietic stem cells to address whether such a therapy could result in a "functional cure" for AIDS patients. Cannon’s research is funded by both the National Institutes of Health and the California Institute for Regenerative Medicine.

HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency J Neurovirol. 2018 Apr; 24(2):192-203. . View in PubMed

Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency Nat Biotechnol. 2018 Jan; 36(1):95-102. . View in PubMed

Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression Nat Commun. 2017 Mar 01; 8:14447. . View in PubMed

Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases Hematol Oncol Clin North Am. 2017 10; 31(5):883-895. . View in PubMed

Clinical Applications of Genome Editing to HIV Cure AIDS Patient Care STDS. 2016 Dec; 30(12):539-544. . View in PubMed

Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment AIDS Patient Care STDS. 2016 Jul; 30(7):291-306. . View in PubMed

International AIDS Society global scientific strategy: towards an HIV cure 2016 Nat Med. 2016 08; 22(8):839-50. . View in PubMed

The clinical applications of genome editing in HIV Blood. 2016 05 26; 127(21):2546-52. . View in PubMed

A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathog Immun. 2016; 1(1):154-164.. View in PubMed

Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells Mol Ther Methods Clin Dev. 2016; 3:16067. . View in PubMed

Nat Biotechnol. 2015 Dec; 33(12):1256-1263. . View in PubMed

Nat Biotechnol. 2015 Dec; 33(12):1256-1263. . View in PubMed

Retrovirology. 2015 Aug 07; 12:67. . View in PubMed

Retrovirology. 2015 Aug 07; 12:67. . View in PubMed

J Virol. 2015 Aug; 89(16):8428-43. . View in PubMed

J Virol. 2015 Aug; 89(16):8428-43. . View in PubMed

Genome editing technologies: defining a path to clinic Mol Ther. 2015 May; 23(5):796-806. . View in PubMed

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges Nature. 2015 Mar 05; 519(7541):87-91. . View in PubMed

Nat Biotechnol. 2014 Apr; 32(4):315-6. . View in PubMed

Nat Biotechnol. 2014 Apr; 32(4):315-6. . View in PubMed

Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice J Infect Dis. 2013 Nov; 208 Suppl 2:S160-4. . View in PubMed

Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases Mol Ther. 2013 Jun; 21(6):1259-69. . View in PubMed

Viruses. 2012 Dec; 4(12):3625-46. . View in PubMed

Viruses. 2012 Dec; 4(12):3625-46. . View in PubMed

J Virol. 2012 May; 86(10):5467-80. . View in PubMed

J Virol. 2012 May; 86(10):5467-80. . View in PubMed

Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP J Virol. 2011 Dec; 85(24):13457-62. . View in PubMed

Lack of adaptation to human tetherin in HIV-1 group O and P Retrovirology. 2011 Sep 28; 8:78. . View in PubMed

Chemokine receptor 5 knockout strategies Curr Opin HIV AIDS. 2011 Jan; 6(1):74-9. . View in PubMed

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo Nat Biotechnol. 2010 Aug; 28(8):839-47. . View in PubMed

Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal J Virol. 2010 Jul; 84(14):7243-55. . View in PubMed

HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment Retrovirology. 2010 Jun 07; 7:51. . View in PubMed

Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu J Virol. 2010 Mar; 84(6):2666-74. . View in PubMed

Anti-tetherin activities in Vpu-expressing primate lentiviruses Retrovirology. 2010 Feb 18; 7:13. . View in PubMed

Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors Retrovirology. 2010 Jan 26; 7:4. . View in PubMed

Investigation of clade B New World arenavirus tropism by using chimeric GP1 proteins J Virol. 2010 Jan; 84(2):1176-82. . View in PubMed

Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system Hum Gene Ther. 2009 Dec; 20(12):1607-26. . View in PubMed

Receptor use by the Whitewater Arroyo virus glycoprotein Virology. 2008 Feb 20; 371(2):439-46. . View in PubMed

New world clade B arenaviruses can use transferrin receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1 J Virol. 2008 Jan; 82(2):938-48. . View in PubMed

Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential Hum Gene Ther. 2007 Sep; 18(9):849-60. . View in PubMed

Differences in tropism and pH dependence for glycoproteins from the Clade B1 arenaviruses: implications for receptor usage and pathogenicity Virology. 2007 Jul 20; 364(1):132-9. . View in PubMed

Receptor use by pathogenic arenaviruses Virology. 2006 Sep 15; 353(1):111-20. . View in PubMed

Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release J Virol. 2006 Mar; 80(6):2924-32. . View in PubMed

Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production J Virol. 2005 Mar; 79(6):3627-38. . View in PubMed

Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide J Virol. 2003 Jan; 77(2):1281-91. . View in PubMed

Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa Nat Genet. 2002 Dec; 32(4):670-5. . View in PubMed

Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype) Virus Res. 2002 Feb 26; 83(1-2):43-56. . View in PubMed

Powered by SC CTSI
Go to Top